Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Insurance
    • US blocks health...

    US blocks health insurer Aetna's $34 billion Humana acquisition

    Written by supriya kashyap kashyap Published On 2017-01-24T11:33:36+05:30  |  Updated On 24 Jan 2017 11:33 AM IST
    US blocks health insurer Aetnas $34 billion Humana acquisition

    A U.S. judge blocked health insurer Aetna Inc's proposed $34 billion acquisition of smaller peer Humana Inc, raising the stakes for rival Anthem Inc as it battles to close a $54 billion deal to buy Cigna Corp.


    The ruling is another victory for the U.S. Justice Department, whose antitrust enforcement became much more aggressive during former U.S. President Barack Obama's eight years in office, which ended last week.


    Obama's successor, Donald Trump, and a Republican-controlled legislature are seeking to undo much of the Affordable Care Act, better known as Obamacare. The law reshaped the U.S. healthcare industry by mandating health insurance and creating online exchanges where consumers can shop for individual policies and get subsidies.


    Aetna, Humana, Anthem and Cigna had cited Obamacare as one of the main reasons their industry needed to consolidate to cope with the costs of expanding coverage. Their shares ended trading on Monday at levels that suggested that investors continued to see little chance that the two mergers would happen.


    The U.S. Justice Department filed a lawsuit last July to block Aetna's acquisition of Humana and Anthem's acquisition of Cigna, arguing that the two deals would lead to higher prices.


    Anthem and Cigna are still waiting for a judge to rule on whether their merger can proceed. Investors have long been skeptical that this deal can be approved, and Leerink Research analyst Ana Gupte reiterated on Monday that she expected to also see this deal blocked.


    In his ruling, Judge John Bates of the U.S. District Court for the District of Columbia said the proposed deal would "substantially lessen competition" in the sale of Medicare Advantage plans in 364 counties in 21 states that the Justice Department had identified in its complaint, and on the Obamacare exchange in three Florida counties.


    "We're reviewing the opinion now and giving serious consideration to an appeal after putting forward a compelling case," Aetna spokesman T.J. Crawford said. Humana did not respond to a request for comment.


    Humana stands to receive a $1 billion breakup fee from Aetna should the deal be abandoned.


    Jeffrey Jacobovitz, a litigator at law firm Arnall Golden Gregory LLP, said that appeals at the D.C. Circuit succeed about one-third of the time and can take a year to resolve. He added that it would be difficult, though not impossible, for Aetna to wait for Trump's new antitrust enforcers to be named and then strike a settlement to save the merger, perhaps by offering to divest more assets.


    Bates dismissed Aetna's argument that there was plenty of choice for consumers because Medicare Advantage, which is managed by insurance companies, competes with traditional Medicare for the elderly and disabled, which is managed by the government.


    "In that (Medicare Advantage) market, which is the primary focus of this case, the merger is presumptively unlawful a conclusion that is strongly supported by direct evidence of head-to-head competition as well. The companies’ rebuttal arguments are not persuasive," Bates wrote in a 158-page decision.


    Humana shares ended trading up 2.2 percent at $205.02, as investors brushed off the widely expected ruling. Shares of Cigna, the other health insurer to be acquired, were almost flat at $145.31


    SEVERAL DEALS TORPEDOED


    Several big deals were torpedoed by antitrust regulators last year, including the $35 billion merger between oil-field service groups Halliburton Co and Baker Hughes Inc and the $6 billion combination of Staples Inc and Office Depot Inc .


    Bill Baer, the former head of the Justice Department's antitrust division who initiated the lawsuit to block the Aetna-Humana deal, called the decision "a strong affirmation of the role that competition plays in health insurance markets."


    Doctors and hospitals had urged the Justice Department to block the deal, fearing it would erode their pricing power. Some large employers also opposed the combination.


    "Today's ruling is a decisive victory for jobs, consumers, and healthcare. Mega mergers like the proposed consolidation of Aetna and Humana raise prices, lower health care quality and kill jobs," said Senator Richard Blumenthal, a Connecticut Democrat.


    Aetna had offered to sell a portfolio of about 290,000 Medicare Advantage members in 21 states to smaller peer Molina Healthcare Inc for $117 million, but that deal failed to appease Judge Bates.


    "We are disappointed by the court's ruling today. However, whatever the ultimate outcome of that litigation, we remain committed to growing our Medicare Advantage product line," Molina spokeswoman Sunny Yu said.


    Humana is the second-largest Medicare Advantage insurer while Aetna is the fourth, and the two compete in more than 600 counties, the government said in its complaint. Despite the adverse regulatory environment, some analysts suggested that an acquisition of Humana by someone other than Aetna was possible.


    "We still suggest other potential M&A optionality exists for Humana, since nothing in the verdict seems to preclude it from possible buyers that expressed historic interest and that have less market overlap, namely Cigna and Anthem, JP Morgan Chase & Co analysts wrote in a note.

    AcquisitionAetnaAffordable Care ActAnthemcignaDonald TrumpHumanaJohn BatesRichard Blumenthal
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok